The Research Executive Committee is closely involved with the program planning and evaluation activities of the UPCI. Discussions regarding the scientific activities and growth ofthe scientific programs are on the agenda on a regular basis. Similarly, the services provided by UPCI shared facilities, operational efficiencies and the need for new services are also discussed regularly. A formal presentation ofthe research activities ofthe CCSG programs, developing programs and services provided bythe shared facilities are presented to the Scientific Advisory Council (SAC) members of UPCI at the annual SAC meeting, following which SAC's feedback and recommendations are discussed at the quarterly Program Leaders and Shared Facility Directors meeting to get their input. The Research Executive Committee continues to discuss extensively the recommendations provided by SAC and the subsequent comments by the Program Leaders and Shared Facility Directors to take the appropriate steps to enhance the programs and shared facilities. The Annual Scientific Retreat provides an outstanding opportunity for lab based faculty, medical and hematologic oncologists, residents, clinical fellows, postdoctoral fellows (lab based) and graduate students to meet together and share ideas. The 2-day event also provides the opportunity to hear presentations from newly recruited faculty members as well as from established UPCI members who have innovative and important research findings. Funds are being requested for two aspects of UPCI's program planning and evaluation activities. These are funds for annual meetings of UPCI's Scientific Advisory Committee, and the UPCI Annual Scientific Retreat.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA047904-26
Application #
8705427
Study Section
Special Emphasis Panel (ZCA1-RTRB-L)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
26
Fiscal Year
2014
Total Cost
$84,479
Indirect Cost
$28,593
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Chen, Lin; Vasilatos, Shauna N; Qin, Ye et al. (2017) Functional characterization of lysine-specific demethylase 2 (LSD2/KDM1B) in breast cancer progression. Oncotarget 8:81737-81753
Kurland, Brenda F; Linden, Hannah M; Mankoff, David A (2017) FDG PET and FES PET Predict PFS on Endocrine Therapy-Response. Clin Cancer Res 23:3475
Jing, Y; Nguyen, M M; Wang, D et al. (2017) DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor. Oncogene :
Lee-Montiel, Felipe T; George, Subin M; Gough, Albert H et al. (2017) Control of oxygen tension recapitulates zone-specific functions in human liver microphysiology systems. Exp Biol Med (Maywood) 242:1617-1632
Gao, Ying; Li, Changling; Wei, Leizhen et al. (2017) SSRP1 Cooperates with PARP and XRCC1 to Facilitate Single-Strand DNA Break Repair by Chromatin Priming. Cancer Res 77:2674-2685
Xie, Yangchun; Zhu, Shan; Zhong, Meizuo et al. (2017) Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma. Gastroenterology 153:1429-1443.e5
von Gruenigen, Vivian E; Huang, Helen Q; Beumer, Jan H et al. (2017) Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. Gynecol Oncol 144:459-467
Pascal, Laura E; Masoodi, Khalid Z; Liu, June et al. (2017) Conditional deletion of ELL2 induces murine prostate intraepithelial neoplasia. J Endocrinol 235:123-136
Tarhini, Ahmad A; Rafique, Imran; Floros, Theofanis et al. (2017) Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer 123:2936-2944
Lothet, Emilie H; Shaw, Kendrick M; Lu, Hui et al. (2017) Selective inhibition of small-diameter axons using infrared light. Sci Rep 7:3275

Showing the most recent 10 out of 1045 publications